跳至主要内容
临床试验/NCT05434598
NCT05434598招募中不适用

A Prospective Study of Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in MDS

Washington University School of Medicine2 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2022年7月27日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
60
试验地点
2
主要终点
Proportion of failed ChromoSeq assays

研究概览

简要总结

This is a single institution, prospective study of the whole genome sequencing assay, ChromoSeq. Using prospectively collected patient data, coupled with physician surveys, the investigators seek to determine the feasibility of implementing ChromoSeq in addition to standard genomic testing, for patients with the diagnosis of myelodysplastic syndrome (MDS).

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Proportion of failed ChromoSeq assays

时间窗: Through completion of all ChromoSeq tests (estimated to be 24 months)

* As compared to failed standard of care genomic profiling assays * The proportion of first-run failures for ChromoSeq assays will be compared to the proportion of failed standard of care genomic profiling assays using a directional Fisher's exact test.

Rate of assay success on first attempt between ChromoSeq and conventional cytogenetics as measured by total number of recurrent structural variants identified

时间窗: Through completion of all ChromoSeq tests (estimated to be 24 months)

-The number of recurrent structural variants detected by ChromoSeq will be compared to those detected by conventional cytogenetics using two non-inferiority tests for dependent samples using non-inferiority margin of 1%.

Rate of assay success on first attempt between ChromoSeq and conventional cytogenetics as measured by total number of copy number alterations identified

时间窗: Through completion of all ChromoSeq tests (estimated to be 24 months)

The number of copy number alterations detected by ChromoSeq will be compared to those detected by conventional cytogenetics using two non-inferiority tests for dependent samples using non-inferiority margin of 1%.

次要结局

  • Stakeholder perceptions of ChromoSeq(Through 1 month after generation of ChromoSeq for all patients enrolled (estimated to be 25 months))

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验